ERBB2 and neoplasm: In clonogenic assays, monospecific 177Lu- and 111In-trastuzumab Fab or EGF only killed tumour cells that expressed HER2 or EGFR, respectively, while the bsRICs were able to kill cells that expressed HER2 or EGFR or both receptors.